I reported previously (Sep 26) that Israel’s Teva had launched a generic version of the cancer treatment Gleevec (imatinib mesylate). What I didn’t realize that Gleevec itself had Israeli origins, being based on work by Weizmann researcher Eli Canaani.  In 2003 Gleevec saved the life of Jewish hockey player and leukemia sufferer Sam Field.

http://www.jta.org/2017/03/08/arts-entertainment/miracle-drug-with-israeli-roots-saves-jewish-hockey-player-hit-with-cancer